TBI 2001
Alternative Names: TBI-2001Latest Information Update: 28 Aug 2023
Price :
$50 *
At a glance
- Originator Takara Bio
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I B-cell lymphoma; Chronic lymphocytic leukaemia
Most Recent Events
- 26 Jul 2023 Phase-I clinical trials in B-cell lymphoma (Second-line therapy or greater) in Canada (IV) (NCT05963217)
- 26 Jul 2023 Phase-I clinical trials in Chronic lymphocytic leukaemia (Second-line therapy or greater) in Canada (IV) (NCT05963217)